Register here, and Gilead will send more information about the CD47 pathway and myeloid malignancies directly to your inbox.

*Indicates required field.

Please fix errors below.

  • Hematologist-Oncologist
  • Hematologist
  • Oncologist
  • Nurse Practitioner/Physician Assistant
  • Registered Nurse/Infusion Nurse
  • Bone Marrow Transplant Physician
  • Pharmacist
  • Other
I agree to the Terms and Conditions.*

CD47, cluster of differentiation 47; NPI, National Provider Identifier.

Terms & Conditions

Gilead respects the privacy of your personal information. Gilead, and companies providing services to Gilead, may use the information that you provide to send you marketing or informational materials about myeloid malignancies and other updates, analyze and use your information to improve or develop services and programs, and contact you about marketing programs or research and health topics that may be of interest to you.

Gilead, and companies providing services to Gilead, will not sell or rent your personally identifiable information. Review our Privacy Policy for more information.